In this line, during the recent 2021 St Gallen International Breast Cancer Conference, more than 80% of the participating experts supported considering extended ET for premenopausal patients with node-positive ER-positive HER2 − breast cancer48. The gene discussed is ERBB2; the disease is breast carcinoma.